An increasing body of information now suggests that insulinlike growth factor (IGF) binding proteins (BPs) may serve as antigonadotropins at the level of the ovary. It is the objective of the present communication to evaluate the functional role of endogenous (granulosa cell-derived) IGFBPs by exploiting the unique properties of des(
Introduction
(FSH) to suppress their constitutive release under both in vitro and in vivo circumstances (1) (2) (3) . Inasmuch as FSH is concerned with the promotion of granulosa cell development, the demonstration of FSH-attenuated IGFBP release strongly suggested that the loss of IGF binding activity may be part and parcel ofgranulosa cell ontogeny, an effect designed to enhance the bioavailability of endogenously generated IGFs. According to this view, soluble IGFBPs may subserve an inhibitory function by sequestering extracellular (granulosa cell-elaborated) IGFs, thereby diminishing their bioavailability. In so doing, IGFBPs may in effect be acting as antigonadotropins in that the IGFs so sequestered are precluded from amplifying the gonadotropic signal (4) . That this in fact may be the case is further supported by recent observations wherein exogenously added IGFBP-1 (5), IGFBP-2 (6), and IGFBP-3 (6) (7) (8) have all been shown to suppress FSH-supported cAMP generation, steroidogenesis, and thymidine incorporation at the level ofthe murine granulosa cell.
To further evaluate the functional role of granulosa cellderived IGFBPs, we have taken advantage ofthe unique properties of a truncated analogue of IGF-I the ability of which to recognize and bind IGFBP-1, IGFBP-2, but not IGFBP-3 (9, 10) has been substantially diminished. Specifically, reference is made to des( 1-3)IGF-I, a naturally occurring (presumptively posttranslationally modified) IGF-I analogue (1 1-14) lacking the amino-terminal tripeptide Gly-Pro-Glu. Indeed, des(l-3)IGF-I (but not intact IGF-I) binding to and activation of type I IGF receptors proved relatively impervious to inhibition by either IGFBP-1 (9, 13) or IGFBP-2 (9) . Although a poor ligand of IGFBPs, des( 1-3)IGF-I is functionally equivalent to IGF-I as a ligand of type I IGF receptors in some (15) (16) (17) but not all ( 12, 13, 18) tissues. Consequent to this constellation of attributes, des( 1-3 )IGF-I is substantially more potent than its intact counterpart in stimulating the growth of a variety of cell types (9-10, 12, 14, 15) .
Implicit in the present experimental approach is the prediction that truncated IGF-I would prove functionally superior to its intact counterpart when assessed under IGFBP-replete circumstances, a functional advantage attributable to relatively limited affinity for endogenously generated IGFBPs. Such observations would be in keeping with the notion that granulosa cell-derived IGFBPs are inhibitory to IGF-I hormonal action.
On the other hand, equipotency of des( (22) .
Radioligand receptor assays. Binding studies were conducted as previously described (23) . Briefly, isolated granulosa cells were homogenized and spun at 600 g for 20 min at 4°C. The first supernatant in turn was spun at 40,000 g for 20 min at 4°C to yield crude plasma membrane preparations. The latter were then incubated with I05 cpm/ tube of [ 1251] IGF and the indicated concentration of the specified experimental agents. At the conclusion ofthe incubation period, the mixtures (total vol of 0.2 ml) were washed twice with 3 ml ice-cold assay buffer to remove excess unbound hormone, and the cell-bound radioactivity in the final pellet determined using a gamma-spectrometer with a counting efficiency of 60%. Nonspecific binding, determined using
[Thr59] IGF-I (1 jg/tube), constituted 1.9% of the total counts added or 9.6% of the total binding (23).
RIA. Medium progesterone content was determined using a specific antiserum (#337) raised again progesterone-l 1-BSA (24), generously provided by Dr. Gordon D. Niswender (Colorado State University, Fort Collins, CO).
Data analysis. Statistical significance was determined by the Student's paired two-tailed t test or analysis of variance as indicated.
Results
To validate the functional utility of des( 1-3 )IGF-I in the context of granulosa cell-derived IGFBPs, use was made of (IGFBP-containing) media conditioned by untreated cultured rat granulosa cells from immature DES-primed rats. Although the exact identity of rat granulosa cell-derived IGFBPs remains unknown, published information indicates the absence of IGFBP-2 (25) . As shown (Fig. 1, left IGFBP-replete circumstances, treatment with increasing concentrations of IGF-I resulted in progressive dose-dependent (ED50 = 4.2±0.8 ng/ml) amplification of FSH hormonal action as assessed in terms of the overall accumulation of progesterone (Fig. 4) . Comparable studies using des( 1-3)IGF-I revealed the truncated analogue (ED50 = 0.44±0.06 ng/ml) to be 10-fold more potent than its native counterpart.
To exclude the possibility that des( 1-3)IGF-I may be acting via the type II 0F able affinity; Fig. 2, right) , we have undertaken to repeat the experiment depicted in Fig. 4 in the presence of neutralizing concentrations ( 100 ,ug/ml) of R-II-PAB1, a previously validated (26) rat type II IGF receptor-directed monoclonal antibody (27) . As shown (Fig. 5) , qualitatively similar results were obtained (relative to R-II-PAB1-negative conditions; Fig. 4 ) thereby arguing against the possibility that the apparent advantage of des( 1-3 )IGF-I is accounted for by its ability to interact at the level of the rat granulosa cell type II IGF receptor. Given that the apparent increase in potency displayed by des( 1-3)IGF-I may be accounted for by its diminished affinity for endogenously derived IGFBPs, we have undertaken to reevaluate des(l-3)IGF-I action under experimental circumstances characterized by the absence of endogenously elaborated IGFBPs. To this end, use was made ofa maximally effective dose of FSH (100 ng/ml), the ability of which to virtually eliminate the production ofgranulosa cell-derived IGFBPs was previously demonstrated ( 1, 3) and herein confirmed (Fig. 3) . Ovarian granulosa cells were cultured for 72 h with or without FSH (100 ng/ml), in the absence or presence of increasing concentrations (0.3-50 ng/ml) of either IGF-I or its des( 1-3)IGF-I analogue. As shown (Fig. 6 ), both des( 1-3)IGF-I and its intact counterpart displayed substantially increased potency (ED50 = 0.6±0.09 ng/ml) relative to that observed for native IGF-I under IGFBP-replete circumstances (ED50 = 4.2±0.8 ng/ml; potent to the unmodified principle, thereby strongly suggesting that the apparently enhanced potency ofdes( 1-3 )IGF-I (under IGFBP-replete conditions) is due to its diminished affinity for endogenously generated IGFBPs. As such, these findings are in keeping with the notion that endogenously derived IGFBPs are inhibitory to IGF-mediated amplification of FSH-supported progesterone biosynthesis hormonal action. This conclusion was further supported by experiments wherein the addition of the amicon-filtered content of media (CM; 1 ml) conditioned by low concentrations (10 ng/ml) of FSH (IGFBP-replete media) effectively attenuated IGF-I hormonal action (Fig. 6) while reaffirming the apparent edge of des( 1-3)IGF-I in this context. The amicon filter mol wt cutoff (10,000) ensured trapping of IGFBPs while eliminating steroidal principles, the retention ofwhich could have rendered the results uninterpretable. Indeed, no immunoreactive progesterone could be detected in amicon-filtered media (not shown).
To ensure that the preceding observations are not des( (Fig. 7, left) , [Gin3, Ala4, Tyr'5, Leu 16] IGF-I displayed substantially diminished affinity for granulosa cell-derived IGFBPs as compared with the unmodified principle. Qualitatively similar results were obtained when using [125I]IGF-II (Fig. 7, right) . In related studies, we have also undertaken to determine the relative affinity of the analogue for rat granulosa cell type I and type II IGF receptors. As shown (Fig. 8, left Fig. 8; right) .
To examine the functional impact of the [Gln3, Ala4, Tyr"5, Leu16] IGF-I analogue, granulosa cells were cultured in the absence or presence of a minimally effective dose of FSH ( 10 ng/ml), with or without increasing concentrations (0.3-50 ng/ml) ofeither IGF-I or its analogues. As shown (Fig. 9, left) , [Gln3, Ala4, Tyr 5, Leu'6]IGF-I (ED50 = 0.8±0.2 ng/ml) proved substantially (five to six times) more potent than its counterpart when tested under IGFBP-replete circumstances. This apparent edge was lost, however, when restudied under IGFBP-deplete circumstances (Fig. 9, right) . As such, these findings suggest that the apparently enhanced potency of regulate not only the transport of IGFs but also their presentation to cognate cell surface receptors (28) . Although the precise role(s) of tissue-derived IGFBPs is a matter of ongoing studies, both stimulation (29, 30) and inhibition (31, 32) of IGF binding and action have been reported. Thus, the synthesis and secretion ofIGFBPs may play a major role in the regulation of IGF hormonal action at the target cell level.
Although the relevance of IGFBPs to ovarian physiology remains unknown, media conditioned by cultured murine granulosa cells were reported to contain IGF binding activity (1) (2) (3) . One such species, IGFBP-1, was localized to luteinized human granulosa cells by immunohistochemistry (33, 34) , radioimmunoassay (34, 35) , immunoisolation (36) , and Northern blotting (37) . Other IGFBP species, i.e., IGFBP-2 and IGFBP-3, were localized to the porcine granulosa cell (38) . In this communication, we seek to reevaluate the role of granulosa cell-derived IGFBPs as it relates to IGF-I hormonal action. Special attention has been paid to the possibility that granulosa cell-derived IGFBPs may inhibit IGF hormonal action, thereby compromising its ability to amplify the gonadotropic signal (4).
Validation of des( 1-3)IGF-I revealed it to display substantially diminished affinity for granulosa cell-derived IGFBPs as compared with the native unmodified principle (Fig. 1) . Although granulosa cell-derived IGFBPs clearly constitute a heterogenous mix of IGF binding species (1) (2) (3) , this material nevertheless represents a more physiologic and thus a more relevant reference preparation. In this respect, our current observations are in keeping with those reported by others wherein the limited affinity ofdes( 1-3)IGF-I to both IGFBP-1 -1so and IGFBP-2 (but not IGFBP-3) has been clearly demonstrated (9, 10). Our present findings further document that des( 1-3)IGF-I effectively binds to type I IGF receptors (Fig. 2, left) . Thus, given that the membranes in question are effectively devoid of IGFBPs (26) , it is highly likely that des( 1-3)IGF-I binding involved type I IGF receptors rather than contaminating IGFBPs. Accordingly, any functional differences between the truncated analogue and its native counterpart cannot be ascribed to differences in binding potencies to the type I IGF receptor. As such, these observations are in keeping with those reported by several investigators wherein des( 1-3)IGF-I proved functionally equivalent to its intact counterpart in terms of binding to type I IGF receptors in some (15) (16) (17) but not all ( 12, 13, 18) tissues and cells so studied. Our current observations (Fig. 2, right) (27) . Experiments reported herein (Fig. 5) (Fig.  4) . Given that such differences cannot be accounted for by divergent interactions at the level of the type I IGF receptor (Fig. 2) , it is highly likely that differences in binding affinity to endogenously derived IGFBPs are at play. As such, these findings are in keeping with the notion that endogenously derived IGFBPs are inhibitory to IGF hormonal action. This notion was further confirmed under experimental conditions charac- terized by the absence of endogenously elaborated IGFBPs. Indeed, given IGFBP-deplete conditions, des( 1-3)IGF-I proved virtually equipotent to the unmodified native principle (Fig. 6 ). Qualitatively comparable observations (Fig. 9 ) made using a similarly endowed (Figs. 7 and 8) IGF-I analogue, i.e., [Gln3, Ala4, Tyr"5, Leu'6]IGF-I.
Taken together, these findings indicate that granulosa cellderived IGFBPs are inhibitory to IGF-mediated amplification of FSH-supported progesterone biosynthesis. Moreover, given the established ability of IGFs to synergize with FSH in the promotion ofgranulosa cell differentiation (4), the present observations are also in keeping with the notion that granulosa cell-produced IGFBPs are in effect inhibitory to gonadotropin (FSH) hormonal action. Accordingly, FSH-attenuated IGFBP release ( 1, 3) may be designed to enhance the bioavailability and hence the access of endogenously generated IGFs to their cognate cell surface receptors, and in so doing, promote FSHsupported progesterone biosynthesis.
